NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for NeuroPace in a research note issued to investors on Wednesday, May 28th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.22) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for NeuroPace's Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.82) EPS and FY2026 earnings at ($0.57) EPS.
NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The company had revenue of $22.52 million during the quarter, compared to the consensus estimate of $21.85 million.
A number of other research analysts also recently weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $17.00 price objective on shares of NeuroPace in a research note on Wednesday, May 14th. JPMorgan Chase & Co. raised their price objective on NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, NeuroPace presently has an average rating of "Moderate Buy" and an average price target of $15.50.
Read Our Latest Research Report on NeuroPace
NeuroPace Stock Performance
Shares of NPCE stock traded down $0.13 during trading on Friday, reaching $12.98. The company had a trading volume of 285,244 shares, compared to its average volume of 160,151. The firm's 50 day simple moving average is $12.83 and its two-hundred day simple moving average is $12.18. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace has a one year low of $5.45 and a one year high of $18.98. The company has a market capitalization of $425.73 million, a PE ratio of -12.98 and a beta of 2.04.
Institutional Trading of NeuroPace
Several institutional investors have recently modified their holdings of NPCE. Rhumbline Advisers boosted its stake in NeuroPace by 15.2% in the 1st quarter. Rhumbline Advisers now owns 17,227 shares of the company's stock valued at $212,000 after buying an additional 2,267 shares in the last quarter. Petrus Trust Company LTA bought a new stake in shares of NeuroPace during the first quarter worth $165,000. First Light Asset Management LLC bought a new stake in shares of NeuroPace during the first quarter worth $19,468,000. Birchview Capital LP raised its position in shares of NeuroPace by 64.4% during the first quarter. Birchview Capital LP now owns 16,442 shares of the company's stock worth $202,000 after acquiring an additional 6,442 shares during the last quarter. Finally, Ghisallo Capital Management LLC bought a new stake in NeuroPace in the first quarter valued at about $2,458,000. Institutional investors and hedge funds own 78.83% of the company's stock.
Insider Buying and Selling at NeuroPace
In other news, major shareholder Orbimed Advisors Llc sold 168,136 shares of NeuroPace stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total transaction of $2,664,955.60. Following the sale, the insider now owns 3,238,199 shares of the company's stock, valued at approximately $51,325,454.15. This trade represents a 4.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.20% of the company's stock.
NeuroPace Company Profile
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Further Reading
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
